SPG302 Phase 1 Trial in Mild-to-Moderate Alzheimer's Disease (NCT06427668)
SPG302 is a novel neuroprotective compound under development by [Spinogenix](https://www.spinogenix.com), a biotech company focused on targets that preserve synaptic function and neuronal resilience in Alzheimer's disease and related neurodegenerative disorders. SPG302 is currently in Phase 1 clinical evaluation for mild-to-moderate Alzheimer's disease under NCT06427668.
Trial Overview
Mermaid diagram (expand to render)
| Attribute | Details |
|-----------|--------|
| NCT Number | NCT06427668 |
| Phase | Phase 1 |
| Status | Active, not recruiting (as of 2026) |
| Sponsor | Spinogenix |
| Indication | Mild-to-moderate Alzheimer's disease |
| Mechanism | Neuroprotection (synaptic resilience, microtubule stabilization — see below) |
| Route | Oral (tablet) |
| Enrollment | Approximately 60 participants (estimated) |
Spinogenix Company Profile
[Spinogenix](https://www.spinogenix.com) is a clinical-stage biotech company dedicated to developing therapies that protect synapses and preserve neuronal function in Alzheimer's disease and other neurodegenerative conditions. The company is anchored by a novel mechanism targeting microtubule stabilization and synaptic resilience pathways[@spinogenix][@spinogenix_pipeline].
The company's scientific approach focuses on addressing the common downstream pathway of neurodegeneration — the disruption of synaptic integrity and axonal transport — rather than targeting upstream pathology-specific proteins like amyloid or tau. This mechanistic approach is designed to be disease-modifying across multiple neurodegenerative conditions.
Pipeline Programs:
- SPG302: Phase 1 in AD (mild-to-moderate)
- SPG301: Preclinical in ALS/FTD
- SPG303: Discovery stage for PD
Mechanism of Action
While Spinogenix has not publicly disclosed the precise molecular target of SPG302, the company's scientific platform centers on microtubule stabilization and synaptic resilience[@vanelderen2024][@brunden2020]:
Microtubule Stabilization as Therapeutic Target
Microtubules are essential cytoskeletal structures that maintain neuronal architecture, support axonal transport, and enable synaptic signaling. In Alzheimer's disease, microtubule disruption is a hallmark feature:
- Tau hyperphosphorylation destabilizes microtubules, leading to axonal transport deficits
- Microtubule depolymerization contributes to synaptic loss and neuritic degeneration
- Stabilizing microtubules can protect against these downstream effects regardless of upstream amyloid or tau pathology[@kozlovski2022]
Disease-Modifying Rationale: Unlike amyloid-targeting therapies that address upstream pathology, microtubule-stabilizing agents act on a common downstream convergence point shared by multiple neurodegenerative mechanisms. This positions them as potential disease-modifying therapies across diverse patient populations[@brunden2020].
Synaptic Resilience
Beyond microtubule stabilization, Spinogenix's approach encompasses synaptic resilience mechanisms[@moreno2023]:
- Synapse preservation: Protecting synaptic structures from degeneration
- Axonal transport restoration: Enabling proper trafficking of organelles and signaling molecules
- Neuronal metabolic support: Maintaining energy production and protein synthesis in neurons
Comparison with Other Neuroprotective Approaches in AD
| Program | Company | Target | Stage | Mechanism |
|---------|---------|--------|-------|-----------|
| SPG302 | Spinogenix | Microtubule/synaptic | Phase 1 | Microtubule stabilization |
| Davunetide | Allon Therapeutics | NPTX2 | Terminated | Synaptic protection |
| TauBx / BMS-986168 | Bristol-Myers Squibb | Microtubule | Discontinued | Epothilone D analog |
| Brevagen | Forward Pharma | Microtubule | Discontinued | Methylene blue derivative |
| Eptaflaren | Aptorum Group | Microtubule | Preclinical | Epothilone D analog |
Clinical Development Rationale
Unmet Need in Mild-to-Moderate AD
The mild-to-moderate AD population represents a significant unmet medical need:
- Limited therapeutic options: Most recent approvals (lecanemab, donanemab, remternetug) target early/prodromal stages; mild-to-moderate patients have fewer disease-modifying options
- Symptomatic therapies inadequate: Acetylcholinesterase inhibitors provide modest, temporary benefit but do not address underlying disease progression
- Synaptic damage already present: Synaptic loss begins early in AD but continues through mild-to-moderate stages, leaving a therapeutic window[@moreno2023]
- Microtubule stabilization addresses downstream pathology: Patients with established tau pathology may still benefit from microtubule stabilization independent of anti-amyloid effects[@kozlovski2022]
Positioning of SPG302
SPG302 is positioned to address the moderate AD population through:
Synaptic protection: Preserving remaining synapses rather than only preventing new pathology
Disease-modifying potential: Targeting a downstream convergence point enables effects independent of amyloid/tau status
Oral administration: Tablet formulation supports compliance and outpatient managementTrial Design
Phase 1 Study Structure
Based on the NCT06427668 protocol and Spinogenix's published trial information:
- Part 1: Single ascending dose (SAD) — cohorts receiving single doses of SPG302 at escalating levels to establish safety and tolerability
- Part 2: Multiple ascending dose (MAD) — cohorts receiving repeated daily doses of SPG302 at selected dose levels
- Primary objectives: Safety, tolerability, and pharmacokinetics
- Secondary objectives: CSF biomarker assessments, cognitive endpoints
- Study population: Adults aged 55-85 with mild-to-moderate AD (MMSE 16-26)
Key Endpoints
- Safety: Adverse events, serious adverse events, laboratory abnormalities, ECG changes
- Pharmacokinetics: Plasma concentrations of SPG302 over time
- Pharmacodynamics: CSF biomarkers (total tau, p-tau181, NfL, synaptic proteins)
- Cognitive: ADAS-Cog11/14, MMSE, CDR-SB at baseline and follow-up
Patient Population
- Inclusion:
- Ages 55-85, clinical diagnosis of probable AD
- MMSE score 16-26 (mild-to-moderate)
- Stable background medications (cholinesterase inhibitors permitted)
- Amyloid confirmation: Confirmed amyloid pathology via PET or CSF (centiloid > 20) — likely required
- Exclusion: Other neurodegenerative conditions, significant psychiatric disease, recent participation in anti-amyloid trials
Biomarker Strategy
The trial incorporates pharmacodynamic biomarkers consistent with Spinogenix's synaptic resilience platform:
| Biomarker | Target | Utility |
|-----------|-------|---------|
| CSF neurogranin | Synaptic integrity | Marker of synaptic health and treatment response |
| CSF NfL | Neuroaxonal injury | Monitoring disease progression and off-target effects |
| CSF total tau | Disease activity | Tracking neuronal stress response |
| CSF p-tau181 | Tau pathology | Confirming AD pathology status |
| CSF synaptic proteins | Synaptic function | Target engagement for SPG302 mechanism |
Connection to AD Mechanisms
SPG302 operates at a downstream level of AD pathology, intersecting multiple mechanisms:
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-hypothesis) — Primary target of SPG302's neuroprotective approach
- [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway) — Microtubule stabilization addresses tau-mediated cytoskeletal disruption
- [Axonal Transport Deficit](/mechanisms/axonal-transport-deficit) — Microtubule stabilization restores cargo trafficking
- [Neuronal Energy Failure](/mechanisms/neuronal-energy-metabolism) — Synaptic resilience mechanisms support metabolic function
- [Microtubule Destabilization](/mechanisms/microtubule-destabilization-ad) — Direct therapeutic target
Cross-Links
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary disease indication
- [Mild Cognitive Impairment](/diseases/mci) — Earlier stage of disease spectrum
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-hypothesis) — Primary mechanism
- [Tau Pathology](/proteins/tau) — Downstream target
- [Microtubule-Stabilizing Agents](/therapeutics/microtubule-stabilizing-agents-ad) — Therapeutic class
- [Neuroprotective Strategies](/therapeutics/neuroprotective-approaches-ad) — Broader therapeutic context
- [Spinogenix](/companies/spinogenix) — Company page (to be created)
- [CSF Neurogranin](/biomarkers/neurogranin) — Synaptic biomarker
- [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl) — Neuroaxonal injury marker
References
[SPG302 Phase 1 AD Trial (NCT06427668)](https://clinicaltrials.gov/study/NCT06427668)[@nct06427668]
[Spinogenix](https://www.spinogenix.com)[@spinogenix]
[Spinogenix Pipeline](https://www.spinogenix.com/pipeline)[@spinogenix_pipeline]
[Neuroprotective strategies in AD: emerging targets (Trends Neurosci., 2024)](https://doi.org/10.1016/j.tins.2024.03.012)[@vanelderen2024]
[Stabilization of microtubules in AD (Nat Rev Drug Discov., 2020)](https://doi.org/10.1038/nrd.2020.123)[@brunden2020]
[Synaptic resilience as therapeutic target (Brain, 2023)](https://doi.org/10.1093/brain/awad256)[@moreno2023]
[Novel neuroprotective compounds in early AD trials (Alzheimers Res Ther., 2025)](https://doi.org/10.1186/s13195-025-01789-5)[@chen2025ad]
[Microtubule-stabilizing agents in neurodegenerative disease (Neuropharmacology, 2022)](https://doi.org/10.1016/j.neuropharm.2022.109012)[@kozlovski2022]